Today: 10 June 2026
Browse Category

NYSE:SNY 16 September 2025 - 17 January 2026

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck & Co shares fell 1.9% to $108.83 Friday after a Reuters report highlighted industry concerns over the FDA’s new fast-track drug approval program. Internal FDA documents show some drug reviews have been delayed due to safety and effectiveness worries, including a patient death linked to Sanofi’s Tzield. The S&P 500 healthcare sector dropped 0.8% amid broader market weakness. Only one drug has been approved under the program so far.
17 January 2026
·····
Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer shares rose 0.3% to $25.67 Thursday as investors weighed U.S. vaccine policy debates and the company’s growth outlook. The stock moved between $25.26 and $25.67 with 22.3 million shares traded. Pfizer will report Q4 results on Feb. 3, with guidance projecting 2026 revenue of $59.5–$62.5 billion and lower COVID-19 product sales. Competition in obesity drugs and AI-driven drug discovery remain in focus.
15 January 2026
····
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer shares fell 0.6% to $25.42 in late-morning trading Thursday as U.S. vaccine policy changes fueled uncertainty. Sanofi warned of weaker U.S. vaccine demand; Pfizer’s CEO criticized the new recommendations. Moderna and Merck also traded lower. Investors await Pfizer’s Feb. 3 results for updates on 2026 outlook and new product pipeline.
15 January 2026
········
Dynavax Technologies (DVAX) Stock After the Bell on Dec. 24, 2025: Sanofi’s $2.2B Buyout, After‑Hours Action, and What to Watch Before the Next Market Open

Dynavax Technologies (DVAX) Stock After the Bell on Dec. 24, 2025: Sanofi’s $2.2B Buyout, After‑Hours Action, and What to Watch Before the Next Market Open

Sanofi agreed to acquire Dynavax Technologies for $15.50 per share in cash, valuing the deal at about $2.2 billion. DVAX shares surged 39% to around $15.45, trading near the offer price after the announcement. Volume topped 30 million shares in a volatile session shortened for the holiday. The transaction is expected to close in Q1 2026, pending customary conditions.
24 December 2025
··
Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Sanofi announced a deal to acquire Dynavax Technologies for $2.2 billion in cash, offering $15.50 per share—a 39% premium to Dynavax’s prior close. DVAX stock jumped about 37% premarket to near the offer price. Dynavax’s board approved the transaction. Closing is expected in Q1 2026, pending regulatory and shareholder approvals.
24 December 2025
···
EU Stock Markets Today (24 December 2025): STOXX 600 Flat on Christmas Eve as BP Castrol Deal, Sanofi’s Dynavax Move and Record Metals Set the Tone

EU Stock Markets Today (24 December 2025): STOXX 600 Flat on Christmas Eve as BP Castrol Deal, Sanofi’s Dynavax Move and Record Metals Set the Tone

The STOXX 600 index was flat at 588.93 by 08:09 GMT on December 24, 2025, as EU stock markets saw sharply reduced liquidity with Germany and Italy closed and other exchanges running shortened sessions for Christmas Eve. Energy shares rose on firmer oil, while miners tracked gains in precious metals. Trading volumes were thin across the continent.
24 December 2025
···
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

President Trump and nine major drugmakers announced deals on Dec. 19 to cut Medicaid and cash-pay drug prices, shifting U.S. pharma policy focus. Shares of most participating firms rose 1%–3%. Trading in the week of Dec. 22–26 is expected to be volatile due to thin holiday liquidity and headline sensitivity. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

President Donald Trump and nine major drugmakers announced deals to cut U.S. drug prices for Medicaid and cash-paying patients, with discounts up to 70% off list prices and a three-year tariff reprieve. Shares of several companies rose modestly after the news. Commitments include free Eliquis for Medicaid and steep discounts on diabetes and migraine drugs. The moves reshape investor expectations for healthcare stocks heading into 2026.
20 December 2025
········
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly will invest $5 billion to build a 200,000-square-foot drug manufacturing plant in Goochland County, Virginia, creating 650 permanent jobs and 1,800 construction jobs. The facility will produce active pharmaceutical ingredients for cancer and autoimmune treatments. The project is part of Lilly’s $27 billion U.S. expansion plan. Virginia approved over $10 million in incentives to secure the site.
16 September 2025
·······

Stock Market Today

  • Why Investors Should Avoid Griffon (GFF) Amid Declining Revenue and Modest EPS Growth
    June 10, 2026, 11:24 AM EDT. Griffon (GFF) trades at $92.27, up 267% since June 2021, outperforming the S&P 500. However, concerns arise as its revenue has declined by 3.1% annually over five years and is forecasted to drop 14.2% in the next year. Earnings per share (EPS) growth, while positive at 6.3% annually over two years, remains modest against revenue declines. Trading at a forward P/E of 16, Griffon's valuation appears fair but with limited upside potential amid looming demand challenges. Analysts suggest caution and recommend considering higher-quality stocks favored by investors like Charlie Munger for better risk-reward balance.

Latest articles

Dow Drops After CPI Surprise, Iran Concerns Keep Fed Outlook Uncertain

Dow Drops After CPI Surprise, Iran Concerns Keep Fed Outlook Uncertain

10 June 2026
Dow drops 0.55% to 50,592 after May CPI jumps 4.2% year-on-year, matching forecasts but fueled by a 7% surge in gasoline prices and rising energy costs, as renewed U.S.-Iran tensions and sharp losses in AI and industrial stocks add to investor caution, with Super Micro Computer plunging 14.2% on $7 billion equity plans and XPO, J.B. Hunt, Old Dominion falling up to 6.2% after Amazon expands freight service.
S&P 500 Swings After Hot CPI, AI Names Under Pressure

S&P 500 Swings After Hot CPI, AI Names Under Pressure

10 June 2026
May inflation jumped 4.2%—the fastest pace since April 2023—matching forecasts but keeping the Fed on hold, as energy prices fueled the rise; S&P 500 and Nasdaq steadied after early losses, but AI-linked stocks slid, with Super Micro Computer tumbling on a $7 billion share sale plan that risks diluting investors.
Chewy Drops After Q1 Beat With Outlook Warning

Chewy Drops After Q1 Beat With Outlook Warning

10 June 2026
Chewy slashed its 2026 net sales outlook to $13.40–$13.55 billion, below prior guidance and analyst estimates, sending shares down 50 cents to $19.90 as investors reacted to weaker-than-expected second-quarter forecasts despite a 7.7% first-quarter sales jump and improved profitability.
Go toTop